Expanding the Vaccine Portfolio for Children and Adults

On October 1, Huons announced that it has signed an exclusive domestic distribution agreement for the Japanese encephalitis live attenuated vaccine 'Imojev' with Substipharm Biologics, a subsidiary of the French global pharmaceutical group Substipharm.


In March 2026, Huons established a dedicated vaccine division and introduced five vaccine products, while upgrading its cold chain infrastructure and specialized sales network for injectables. By bringing Imojev into its portfolio, the company expects to create synergies with its existing vaccine products and further strengthen the market competitiveness and sales capabilities of its vaccine division.


Huons Signs Agreement with Substipharm for Introduction of Japanese Encephalitis Live Vaccine 'Imojev' View original image

Imojev is a live attenuated Japanese encephalitis vaccine indicated for children aged 12 months and older, as well as adults. While conventional inactivated vaccines require up to five complex doses for children, Imojev offers the advantage of a simplified schedule—only two doses for children and a single dose for adults are sufficient for completion.


The two companies plan to continue their close partnership to establish a stable vaccine supply system and provide trusted immunization solutions for medical professionals and patients in Korea.



Soo-Young Song, CEO of Huons, stated, "We will continue to reliably expand our product portfolio, work to safeguard public health, and make ongoing efforts to improve the nation's healthcare environment."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing